Rifampicin-resistance Pattern of Mycobacterium Tuberculosis and Associated Risk Factors Among Presumptive Pulmonary and Extra Pulmonary Tuberculosis Patients at Madda Walabu University Goba Referral Hospital, Southeast Ethiopia

Abstract

Background: Drug resistant M.tuberculosis is one of the serious public health trouble that intimidating progress made in tuberculosis cases and control in several countries. Early detection of drug-resistant tuberculosis is crucial for patient management and infection control. Methods: Hospital based cross-sectional study design was conducted from October 2020 to February 2021. Detection of Mycobacterium tuberculosis and resistance to Rifampicin pattern was determined by using GeneXpert MTB/RIF assay. Data were entered and analyzed by SPSS version 23.0. Bivariate and multivariate analyses were used to examine the relationship between dependent and independent variables. Less than 0.05 P-value was used to show significance.Results: A total of 301 presumptive tuberculosis patients were included in the study; of these, 46 (15.3%) of them were identified as having Mycobacterium tuberculosis, 2/46 (4.35%) were resistant to Rifampicin and 4/46 (14.8%) patients were TB/HIV co-infected. From the total of M. tuberculosis detected 40 (16.7%) were identified in pulmonary and 6 (9.8%) were in extra-pulmonary presumptive patients. Rifampicin-resistant M. tuberculosis was detected in 2 patients who had a history of taking Anti-tuberculosis drugs. Conclusion: Previous history of tuberculosis treatment and having close contact history with tuberculosis patients were found as important associated factors that enhance the prevalence of tuberculosis among presumptive tuberculosis patients. This indicates the mandate to make better and oversee the treatment protocol to control the burden of drug resistant M.tuberculosis.

Burden of Mycobacterium tuberculosis and Associated Factors among Presumptive Extra pulmonary Tuberculosis Patients from Selected Health Facilities, Addis Ababa, Ethiopia

“…The frequency of EPTB (MTBC) according to the Xpert MTB/RIF assay was consistent with studies conducted in Morocco (20.6%), and findings from Goba, southeast Ethiopia (15.3%) [ 12 , 13 ]. Our findings showed that the prevalence of MTBC was lower than in studies conducted in Dessie (23.4%), Gondar (26.2%), and Addis Ababa (49.3%) [14] , [15] , [16] .…”

“…The presence of contact history with known TB patients increased the chance of becoming diseased to four times more than for those who had no contact history. This finding was supported by studies conducted in Goba and Gondar [ 13 , 15 ]. In our study, TBL was the most common confirmed type of EPTB (71.1%).…”

Pulmonary tuberculosis and multidrug-resistant Mycobacterium tuberculosis in northwestern Ethiopia: a hospital-based cross-sectional study among presumptive pulmonary tuberculosis patients

“…In December 2010, the World Health Organization (WHO) approved Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA). This automated molecular system detects both MTB and rifampicin-resistant (RR) tuberculosis concurrently to address the issue of early TB diagnosis in low-income countries ( 7 ). In over 90% of cases, RR-MTB is a surrogate marker for MDR-TB.…”